Skin Cancer

Skin Cancer

Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile

Demographic and clinical-pathological variables are analyzed to measure their impact on patient survival in this cohort of CMM patients.

Frontiers in Oncology
Treatment Sequence Impacts Survival in BRAF-Mutant Metastatic Melanoma

Treatment sequence can impact survival in patients with BRAF V600-mutant metastatic melanoma, according to results from the phase 3 DREAMseq trial.

Cancer Therapy Advisor
‘Better Biomarkers are Needed’ as Treatment Options for Advanced Melanoma Increase

Approvals of BRAF-targeted therapies and immune checkpoint inhibitors have greatly expanded the melanoma treatment landscape during the past decade. 


Immunotherapy Before Targeted Therapy Extends OS in Metastatic Melanoma

Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer...

Achieving Integrated Self-Directed Cancer Aftercare for Melanoma

To support survivors, the ASICA intervention was developed to prompt and improve TSSE performance, with subsequent reporting of concerns and submission of skin photos to a DNP.

BMC Cancer
Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy

Research assesses the cost-effectiveness of ipilimumab plus anti-PD-1 therapy in this population from the US payer perspective.

Frontiers in Oncology
Pattern Recognition Receptors in Macrophages Possess Prognosis and Immunotherapy Potential for Melanoma

Researchers analyzed the correlations between PRR genes and the prognosis of many different cancers and found PRR genes highly positive corelated with the prognosis of SKCM. 

Frontiers in Immunology
Risks and Benefits of Reinduction Ipilimumab/Nivolumab in Melanoma Patients Previously Treated With Ipilimumab/Nivolumab

Scientists observe patient reaction to reintroducing ipilimumab/nivolumab to melanoma patients who progress after prior ipilimumab/nivolumab combination immunotherapy.

Journal for ImmunoTherapy of Cancer
Types of Second Primary Cancer Influence Overall Survival in Cutaneous Melanoma

The influence of patient characteristics at diagnosis of first melanoma and the type of SPC (second melanoma and other SPC) on overall survival is assessed by researchers. 

BMC Cancer
The Hedgehog-GLI Pathway Regulates MEK5-ERK5 Expression and Activation in Melanoma Cells

Researchers find ERK5 is required for Hedgehog-GLI-dependent melanoma cell proliferation, and the combination of GLI and ERK5 inhibitors is more effective than single treatments...

International Journal of Molecular Sciences
SECOMBIT Trial Evaluates Optimal Treatment Sequencing in BRAF-Mutated Melanoma

Patients with untreated metastatic BRAF-mutated melanoma may benefit from receiving immunotherapy first, then moving to targeted therapy suggests the randomized, phase II SECOMBIT trial.

The ASCO Post
DLEU1 Promotes Oral Squamous Cell Carcinoma Progression by Activating Interferon-Stimulated Genes

Scientists find that DLEU1 exerts its oncogenic effects, at least in part, through activation of a series ISGs in OSCC cells.

Scientific Reports
Integration Analysis of m6A Related Genes in Skin Cutaneous Melanoma and the Biological Function Research of the SPRR1B

Research provides a new view for the comprehensive action of m6A regulatory factors & for the first time finds SPRR1B can promote the proliferation, invasion & migration of melanoma cells <

Frontiers in Oncology
Integrative Characterization of the Role of IL27 In Melanoma Using Bioinformatics Analysis

Scientists work to uncover the multifaceted roles of IL27 and provide evidence for future cytokine-based immunotherapy against melanoma.

Frontiers in Immunology
Nobiletin-Loaded Composite Penetration Enhancer Vesicles Restore the Normal miRNA Expression and the Chief Defence Antioxidant Levels in Skin Cancer

This study is the first attempt to evaluate the effect of nobiletin on antioxidant enzymes and mi-RNAs in the treatment of skin cancer.

Scientific Reports
Adjuvant Pembrolizumab Shows Efficacy in High-Risk Stage II Melanoma in Adults and Children Older Than 12

According to a late-breaking interim analysis of the phase III KEYNOTE-716 trial, adjuvant pembrolizumab reduced the risk of recurrence in adults and children older than age 12...

The ASCO Post
HSP105 Expression in Cutaneous Malignant Melanoma: Correlation with Clinicopathological Characteristics

Scientists analyzed the relationship between HSP105 expression and the clinicopathological characteristics of CMM.

Skin Cancer Harbors Targetable Mutation

An especially deadly subtype of T-cell lymphoma is distinguished by unique mutations in a specific protein signaling pathway.

Medical Xpress
Integrating Additional Factors into the TNM Staging for Cutaneous Melanoma by Machine Learning

Scientists introduce machine learning as a novel tool that incorporates additional prognostic factors to improve the current TNM staging system.

Identification of Neutralizing Pembrolizumab Anti-Drug Antibodies in Patients With Melanoma

This study aimed to evaluate the usefulness of these assays in measuring drug levels and ADAs in patients being treated with pembrolizumab monotherapy for melanoma in “real-world” settings. 

Scientific Reports
Non-Melanoma Skin Cancer Diagnosis: A Comparison Between Dermoscopic and Smartphone Images by Unified Visual and Sonification Deep Learning Algorithms

This study evaluated by a dual CNN performance metrics in DI versus SI and tested if artificial intelligence narrows the proclaimed gap in diagnostic accuracy.

Journal of Cancer Research and Clinical Oncology
Pituitary Adenylate Cyclase Activating Polypeptide Has Inhibitory Effects on Melanoma Cell Proliferation and Migration In Vitro

Researchers provide evidence that PACAP receptors are expressed by normal and malignant cutaneous pigment cells deriving from two different stages of malignancy and PACAP signalling...

Frontiers in Oncology
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma

Scientists investigate digital PD-L1 quantification versus physician PD-L1 quantification in pre-treatment tumor tissue...

Frontiers in Oncology
Optimizing Texting Interventions for Melanoma Prevention and Early Detection

Researchers establish the optimal text messaging intervention to achieve behavior change in young adults at risk of skin cancer.

Prevention, Early Detection, and Interception
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

This phase II cohort from PIVOT-02 study evaluates the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin plus nivolumab in first-line metastatic melanoma.

Journal of Clinical Oncology
Immunotherapy Combo Checks Progression in Advanced Melanoma

Researchers have used two immunotherapy drugs to target and block different protein checkpoints, significantly increasing the time before melanoma progressed in new patients with...

Oncology Times - Latest Articles
PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

Investigators retrospectively analyze plasma DNA of patients with advanced melanoma treated with PD-1 antibodies, nivolumab or pembrolizumab, for five PD-1 genotype single nucleotide polymorphisms.

Frontiers in Immunology
High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma

Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery.

The ASCO Post
Ultrasound-Mediated Microbubble Destruction Inhibits Skin Melanoma Growth by Affecting YAP1 Translation Using Ribosome Imprinting Sequencing

In this study, tumor tissue samples are collected from 64 CMM patients.

Frontiers in Oncology
Health-Related Quality of Life With Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma

An analysis of this trial shows no clinically significant decline in health-related quality of life with adjuvant pembrolizumab vs placebo in resected high-risk stage III melanoma. 

The ASCO Post
Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma

Current guidelines for postoperative management of patients with stage I-IIA cutaneous melanoma do not recommend routine cross-sectional imaging...

JCO Precision Oncology
Patterns in the Development of Melanoma Across Body Sites

An international research team examined patterns in the development of melanoma in patients in Australia and the United Kingdom and shed light on possible relationships by anatomical site.

Cancer Therapy Advisor
Systemic Photoprotection in Skin Cancer Prevention: Knowledge Among Dermatologists

The aim of this study is to summarize the current state of knowledge of systemic photoprotection and to evaluate the knowledge and attitude of dermatologists regarding these treatments.


source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(235, 64, 52)